据美国证券交易委员会（SEC）文件披露，Lisata Therapeutics（证券代码：LSTA）对其财务状况进行了最新预估。该公司预计，在截至2026年9月30日的季度内，与其裁员计划相关的总成本将高达120万美元。这一数字涵盖了此次人力资源调整所产生的各项直接与间接费用，正式揭开了企业战略收缩下的财务影响。
据美国证券交易委员会（SEC）文件披露，Lisata Therapeutics（证券代码：LSTA）对其财务状况进行了最新预估。该公司预计，在截至2026年9月30日的季度内，与其裁员计划相关的总成本将高达120万美元。这一数字涵盖了此次人力资源调整所产生的各项直接与间接费用，正式揭开了企业战略收缩下的财务影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.